The severe acute respiratory syndrome associated coronavirus‑2 (SARS‑CoV‑2) poses a
threat to human life worldwide. Since early March, 2020, coronavirus disease 2019 (COVID …

The potential immune intersection between COVID-19 disease and cancer therapy raises
important practical clinical questions and highlights multiple scientific gaps to be filled …

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a
pandemic by the WHO that claimed the lives of thousands of people within a few months …

COVID-19 infections are characterized by inflammation of the lungs and other organs that
ranges from mild and asymptomatic to fulminant and fatal. Patients who are …

The coronavirus disease 2019 (COVID-19) is currently representing a global health threat
especially for fragile individuals, such as cancer patients. It was demonstrated that cancer …

While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded
4.7 million globally, scientists are pushing forward with efforts to develop vaccines and …

Conclusion Clinical decisions about cancer patients deserving immunotherapy in the current
context of the COVID-19 pandemic should be characterized by separated reflections …

Introduction Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is
administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the …

The immunomodulatory effects of immune-checkpoint blockade (ICB) therapy for cancer
may act at the crossroads between the need to increase antiviral immune responses to …

Background During COVID‐19 outbreak, oncological care has been reorganized. Patients
with cancer have been reported to experience a more severe COVID‐19 syndrome; …